|Synonyms||2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid, Adenuric, Atenuri, Uloric|
|Keywords||Gout, Chronic hyperuricemia|
|Related products||Colchicine, Acerola Cherry Extract|
|CAS Registry Number||144060-53-7|
|Molecular Weight||316.4 g/mol|
|Shelf life||2 years|
|Functions||Treatment of gout, Chronic hyperuricemia|
Febuxostat is an anti-gout medicine. Febuxostat has a significant inhibitory effect on both oxidized and reduced XOR. Febuxostat is used to lower uric acid levels in people with gout. Febuxostat works by reducing the amount of uric acid made by the body.
Febuxostat is used to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. This medicine is a xanthine oxidase inhibitor. It works by causing less uric acid to be produced by the body.
- Okamoto, K., Eger, B.T., Nishino, T., et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J. Biol. Chem. 278(3), 1848-1855 (2003).
- Bisht, M., and Bist, S.S. Febuxostat: A novel agent for management of hyperuricemia in gout. Indian J. Pharm. Sci. 73(6), 597-600 (2011).
- Honorat, J.A., Nakatsuji, Y., Shimizu, M., et al. Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. PLoS One 12(11), e0187215 (2017).